Faecal immunochemical test to detect colorectal neoplasia in Lynch syndrome – a prospective multicentre study
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S76-S77
DOI: 10.1055/s-0044-1782854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von E. van Liere und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Aims
Colonoscopy surveillance for Lynch syndrome is burdensome and post-colonoscopy colorectal cancers (CRCs) still occur. The non-invasive faecal immunochemical test (FIT) might guide optimal colonoscopy intervals.
Methods
Prospective, multi-centre observational study in which individuals with Lynch syndrome performed a quantitative FIT prior to high-quality surveillance colonoscopy. Diagnostic performance of FIT at various thresholds≤20 μg/g was assessed for relevant neoplasia, including advanced neoplasia (CRC, advanced adenomas [AA] and advanced serrated lesions [ASL]) and non-advanced adenomas (NAA).
Results
Of the 217 included individuals (59% female, median age 51 years), 4 had CRC, 5 AA, 4 ASL and 57 NAA as most relevant neoplasia. The lowest FIT positivity threshold (2.55 μg/g, 14% positivity rate) maximised detection: 4/4 CRCs, 4/5 AA, 1/4 ASL and 9/57 NAA were detected, resulting in a sensitivity and negative predictive value (NPV) of, respectively, 89% and 99% for CRC plus AA, 69% and 97% for advanced neoplasia, and 26% and 72% for all relevant neoplasia (91% specificity for all groups). At equal sensitivity and NPV, specificity for advanced neoplasia optimised to 94% at threshold 4.08 μg/g. Per 100 FITs at threshold 4.08 μg/g, 11 individuals would test positive and thus be referred for colonoscopy, 2 individuals with advanced neoplasia would be missed and 3 individuals would need colonoscopy to detect 1 advanced neoplasia.
Conclusions
FIT≤4.08 μg/g may be a safe strategy to postpone colonoscopy in approximately 9 out of 10 individuals with Lynch syndrome. Large validation studies that also provide gene mutation-specific outcomes should be prioritised. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Liere, E. V., Boer, N. D., Leerdam, M. V., Dekker, E., Jacobs, M., Koornstra, J. J., Kuijvenhoven, J., Lemmens, M., Meijer, G., Spaander, M., Carvalho, B., & Ramsoekh, D. (2024). Faecal immunochemical test to detect colorectal neoplasia in Lynch syndrome – a prospective multicentre study. Endoscopy, 56(S 02 S 02), S76-S77. https://doi.org/10.1055/s-0044-1782854
Vancouver
Liere EV, Boer ND, Leerdam MV, Dekker E, Jacobs M, Koornstra JJ, et al. Faecal immunochemical test to detect colorectal neoplasia in Lynch syndrome – a prospective multicentre study. Endoscopy. 2024;56(S 02 S 02):S76-S77. doi:10.1055/s-0044-1782854
BibTeX
@article{Liere2024,
author = {Liere, E. van and Boer, N. De and Leerdam, M. Van and Dekker, E. and Jacobs, M. and Koornstra, J. J. and Kuijvenhoven, J. and Lemmens, M. and Meijer, G. and Spaander, M. and Carvalho, B. and Ramsoekh, D.},
title = {Faecal immunochemical test to detect colorectal neoplasia in Lynch syndrome – a prospective multicentre study},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S76--S77},
doi = {10.1055/s-0044-1782854}
}
EUVIMED